Cardiovascular disturbances in acromegaly;Distúrbios cardiovasculares na acromegalia

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 9, 2008, Pages 1416-1429

  Fedrizzi, Daniela ^a   Czepielewski, Mauro Antonio ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b NONE

Author keywords

Acromegalic cardiomyopathy; Acromegaly; Cardiovascular risk; Secondary hypertension

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; CARDIOMEGALY; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MALE; METABOLISM; MIDDLE AGED; REVIEW; SECRETION; VALVULAR HEART DISEASE;

ACROMEGALY; ADULT; AGED; ARRHYTHMIAS, CARDIAC; CARDIOMEGALY; FEMALE; HEART DISEASES; HEART VALVE DISEASES; HUMAN GROWTH HORMONE; HUMANS; HYPERTENSION; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 60149094172     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000900004     Document Type: Review

References (69)

1. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2(1):29-41.
2. Melmed S. Acromegaly. In: Melmed S, ed. The Pituitary. Massachusets: Blackwell Publishing. 2002. p.419-54.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-52.
4. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558-73.
5. Vitale G, Pivonello R, Lombardi G, Colao A. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Treat Endocrinol. 2004;3(5):309-18.
6. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev. 2003;24(3):272-7.
7. Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani S, Kouhara H, et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf). 2001;54(6):791-6.
8. Katznelson L. Current thinking on the management of the acromegalic patient. Curr Opin Endocrinol Diabetes Obes. 2007;14(4):311-6.
9. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4):439-46.
10. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metabolism. 2004;89(2):667-74.
11. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metabolism. 2008;93(1):61-7.
12. Casagrande A, Czepielewski MA. Growth hormone (GH) and IGF-I assays: methodological aspects and its implications in acromegaly diagnosis and follow-up. Arq Bras Endocrinol Metabol. 2007;51(4):511-9.
13. Minniti G, Jaffrain-Rea ML, Moroni C, Baldelli R, Ferretti E, Cassone R, et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol (Oxf). 1998;49(1):101-6.
14. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clinical Endocrinology. 2001;54(2):137-54.
15. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15(5):555-73.
16. Vitale G, Galderisi M, Pivonello R, Spinelli L, Ciccarelli A, de Divitiis O, et al. Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass. Clin Endocrinol (Oxf). 2004;60(3): 343-9.
17. Fazio S, Cittadini A, Biondi B, Palmieri EA, Riccio G, Bone F, et al. Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metabolism. 2000;85(1):179-82.
18. Casini AF, Araujo PB, Fontes R, Xavier SS, Gadelha MR. Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly. Arq Bras Endocrinol Metabol. 2006;50(1):82-90.
19. Lopez-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metabolism. 1997;82(4):1047-53.
20. Swearingen B, Barker FG, 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metabolism. 1998;83(10):3419-26.
21. Baldwin A, Cundy T, Butler J, Timmis AD. Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Acta Endocrinol (Copenh). 1985;108(1):26-30.
22. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metabolism. 2001;86(4):1551-7.
23. Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affricano C, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf). 2001;55(3):307-13.
24. Ciulla MM, Epaminonda P, Paliotti R, Barelli MV, Ronchi C, Cappiello V, et al. Evaluation of cardiac structure by echorefl ectivity analysis in acromegaly: effects of treatment. Eur J Endocrinol. 2004;151(2):179-86.
25. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf). 2003;58(2):169-76.
26. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metabolism. 2007;92(5):1743-7.
27. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metabolism. 2007;92(2): 476-82.
28. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, et al. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13(1):51-6.
29. Fatti LM, Scacchi M, Lavezzi E, Pecori Giraldi F, De Martin M, Toja P, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf). 2006;65(5):626-30.
30. Herrmann BL, Bruch C, Saller B, Ferdin S, Dagres N, Ose C, et al. Occurrence of ventricular late potentials in patients with active acromegaly. Clin Endocrinol (Oxf). 2001;55(2):201-7.
31. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest. 2002;25(11):971-6.
32. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metabolism. 2003;88(7):3196-201.
33. Lie JT. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 1980;100(1):41-52.
34. Ohtsuka G, Aomi S, Koyanagi H, Tsukui H, Tomizawa Y, Hashimoto A, et al. Heart valve operation in acromegaly. Ann Thorac Surg. 1997;64(2):390-3.
35. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metabolism. 2004;89(1):71-5.
36. van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res. 2006 Apr;16(2):101-7.
37. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356(1):39-46.
38. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29-38.
39. Ross R. Atherosclerosis-an inflammatory disease. New England Journal of Medicine. 1999;340(2):115-26.
40. Chanson P, Megnien JL, del Pino M, Coirault C, Merli I, Houdouin L, et al. Decreased regional blood flow in patients with acromegaly. Clin Endocrinol (Oxf). 1998;49(6):725-31.
41. Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf). 2000;53(4):445-51.
42. Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, di Somma C, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metabolism. 2002;87(7):3174-9.
43. Schiavon F, Maffei P, Martini C, De Carlo E, Fais C, Todesco S, et al. Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metabolism. 1999;84(9):3151-5.
44. Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf). 2001;54(4):515-24.
45. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metabolism. 2005;90(7):4081-6.
46. Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, et al. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metabolism. 2006;91(10):3766-72.
47. Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metabolism. 2007;92(11):4271-7.
48. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf). 2005;63(4):470-6.
49. Mulatero P, Veglio F, Maffei P, Bondanelli M, Bovio S, Daffara F, et al. CYP11B2-344T/C gene polymorphism and blood pressure in patients with acromegaly. J Clin Endocrinol Metabolism. 2006;91(12):5008-12.
50. Andreassen M, Faber J, Vestergaard H, Kistorp C, Kristensen LO. N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clin Endocrinol (Oxf). 2007;66(5):619-25.
51. Smith JC, Lane H, Davies N, Evans LM, Cockcroft J, Scanlon MF, et al. The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metabolism. 2003;88(6):2556-61.
52. Rizzoni D, Porteri E, Giustina A, De Ciuceis C, Sleiman I, Boari GE, et al. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension. 2004;43(3):561-5.
53. Rio GD, Velardo A, Mascadri C, Zalteri G, Papi G, Menozzi R, et al. Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion. Eur J Endocrinol. 2000;142(2):179-86.
54. Bondanelli M, Ambrosio MR, Franceschetti P, Margutti A, Trasforini G, Degli Uberti EC. Diurnal rhythm of plasma catecholamines in acromegaly. J Clin Endocrinol Metabolism. 1999;84(7):2458-67.
55. Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M, et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf). 2001;54(2):189-95.
56. Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev. 1996;17(5):423-80.
57. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metabolism. 2000;85(1):193-9.
58. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metabolism. 2006;91(1):121-8.
59. Maffei P, Sicolo N, Plebani M. Lipoprotein(a) in acromegaly. Ann Intern Med. 1999;130(6):537-8.
60. Maldonado Castro GF, Escobar-Morreale HF, Ortega H, Gomez-Coronado D, Balsa Barro JA, Varela C, et al. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clin Endocrinol (Oxf). 2000;53(3):313-9.
61. Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract. 2007;13(4):363-72.
62. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol. 1995;133(4):430-9.
63. Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res. 2001;34(11):1429-33.
64. Baldelli R, De Marinis L, Bianchi A, Pivonello R, Gasco V, Auriemma R, et al. Microalbuminuria and insulin sensitivity in patients with Gh-secreting pituitary tumor. J Clin Endocrinol Metabolism. 2008;93(3):710-4.
65. Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res. 2002;12(6):418-24.
66. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754-9.
67. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metabolism. 2002;87(4):1692-9.
68. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf). 2002;56(3):303-11.
69. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metabolism. 1998;83(8):2730-4.